Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 528

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 528
---
 of the differences between being a shareholder of Kadimastem and a shareholder of NLS. Copies of the documents referred to in this summary may be obtained as described under the section entitled “ Where You Can Find More Information.” The discussion in this section does not include a description of rights or obligations under the U.S. federal securities laws or Nasdaq listing requirements. Summary of Material Differences Between the Rights of Kadimastem Shareholders and NL Shareholders

| Rights of Kadimastem shareholders                                                                                      |     | Rights of NLS Pharmaceutics shareholders                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Share Capital                                                                                                          |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| The authorized share capital of Kadimastem consists of 15,000,000 (fifteen million) ordinary shares with no par value. |     | The share capital of NLS as of the date of this proxy statement/prospectus amounts to CHF 184,738.14 divided into 4,908,034 fully paid-in registered shares (NLS Common Shares) and 1,249,904 fully paid-in registered shares (NLS Preferred Shares), each with a par value of CHF 0.03 and a participation capital (non-voting capital) of CHF 18,193.56, divided into 606,452 fully paid-in participation certificates (preferred participation certificates), with a par value of CHF 0.03 each. 
 The share capital of NLS after the Merger shall amount to CHF 228,473.94, divided into 3,745,402 fully paid-in registered shares (Common Shares), and 62,497 fully paid-in registered shares (Preferred Shares), each with a par value of at least CHF 0.06 and a participation capital (non-voting capital) of CHF 1,819.44, divided into 30,324 fully paid-in participation certificates (Preferred Participation Certificates), with a par value of at least CHF 0.06 each.                      |

288

| Rights of Kadimastem shareholders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |     | Rights of NLS Pharmaceutics shareholders                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |     | Capital band (Kapitalband)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
 The articles of association may authorize the NLS Board to increase the share capital (within a period of no more than five years) and set forth the nominal amount by which the NLS Board may increase the share capital